Home | Structured Search | Drug Resource
Find: within
Heatstroke > Non-drug Therapy Author: Dani Moran, PhD; Moshe Rav-Acha, MD; Liran Mendel, BMedSc
Module updated - 2009-08-19
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • Heatstroke prognosis is thought to depend on the time period during which the rectal temperature is above a critical value (40°C [104°F]); therefore, the importance of rapid efficient cooling such as by immersion in ice water cannot be overemphasized.

Evidence:

  • Hospital treatment for heatstroke should emphasize whole body cooling (4; 9; 20; 21; 22; 23).
  • No evidence supports the superiority of any one cooling technique in patients with classic heatstroke (24).

Comments:

  • Immediate initiation of cooling as soon as a diagnosis is reached is the cornerstone of treatment.
  • Cooling by ice water can provoke shivering thermogenesis, thus lowering the cooling rate. Cardiac arrhythmias have also been provoked by ice water immersion. Therefore, in certain populations, such as elderly persons or patients with prior cardiovascular illness, use of ice water may be harmful (20; 25). Tepid water (26°C [78.8°F]) immersion may induce cooling at similar rates as ice water without coincident risk of complications (26). It is important to stop cooling when body core temperature reaches 38°C (100.4°F) to prevent over cooling (9).

FAQs
Dani Moran, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. James Glazer, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Liran Mendel, BMedSc has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Moshe Rav-Acha, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.